
U.S. Physical Therapy, Inc.: stock overview
Price
$99.60
November 13, 2026Market cap $1.5B
What Ploutos Investor adds for U.S. Physical Therapy
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
U.S. Physical Therapy had revenue of $838M over the last 12 months and net income of $30M, a net margin of 3.6%. Revenue grew by 13.1% a year on average over the last 5 years. At $99.60 the shares trade at a P/E of 50.0, against a median of 48.2 over the last 5 fiscal years. It has net debt of $208M. It pays a dividend yielding 1.84%.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.
Its SEC filings- Market cap
- $1.5B
- 15.12M shares
- P/E
- 50.0
- Today50.0Median48.2
- Revenue, 12 months
- $838M
- +13.1% a year over 5 years
- Net margin
- 3.6%
- 2025: 5.1%, above 71% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+13.6% a year over 2 years
Fiscal years in figures
USPH's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $1.3B
- $1.5B
- Enterprise value
- $1.7B
- P/E 3-year median: 55.0
- 50.0
- EV / EBIT
- 22.5
- EV / Revenue
- 2.1
- P/B 3-year median: 2.8
- 3.5
- FCF yield 3-year median: 5.2%
- 4.6%
- Earnings yield 3-year median: 1.8%
- 2.0%
Profitability
- Gross margin
- 18.9%
- Operating margin
- 9.1%
- Net margin 3-year median: 4.7%
- 3.6%
- ROIC
- 8.6%
- ROIC, 5-year average
- 9.5%
- ROE
- 6.5%
Growth
- Revenue, yearly change
- +16.3%
- EPS, yearly change
- -22.8%
- FCF, yearly change
- -7.2%
- Revenue, average a year
- +13.1%
- EPS, average a year
- -10.5%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $38M
- Total debt
- $420M
- Of which operating leases
- $174M
- Net debt
- $208M
- Net debt / EBITDA
- 2.1x
- Interest cover
- –
- Current ratio
- 1.42
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield 3-year median: 2.0%
- 1.84%
- Buybacks
- 0.37%
- Total returned
- 2.21%
- Shares, yearly change
- -0.5%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 80).
Gross margin
19.2%
Above 18% of the 25 companies in its industry, and 21% of all.
Operating margin
11.1%
Above 81% of the 62 companies in its industry, and 67% of all.
Net margin
5.1%
Above 71% of the 68 companies in its industry, and 52% of all.
ROE
8.3%
Above 59% of the 58 companies in its industry, and 54% of all.
ROA
3.3%
Above 63% of the 69 companies in its industry, and 63% of all.
Revenue growth
16.3%
Above 62% of the 68 companies in its industry, and 75% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- U S PHYSICAL THERAPY INC /NV
- CIK
- 885978
- Exchange
- NYSE
- Industry (SIC)
- 8000 · Services-Health Services
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 15.12M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with USPH
- JNJJohnson & Johnson+0,00%Compare with USPH
- ABBVAbbVie+0,00%Compare with USPH
- UNHUnitedHealth+0,00%Compare with USPH
- MRKMerck & Company+0,00%Compare with USPH
- AMGNAmgen+0,00%Compare with USPH
- TMOThermo Fisher Scientific+0,00%Compare with USPH
- ABTAbbott Laboratories+0,00%Compare with USPH
The full analysis
What do U.S. Physical Therapy's filings show?
These are U.S. Physical Therapy's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is USPH's market cap?
U.S. Physical Therapy, Inc.'s market cap is $1.5B, at a price of $99.60 on November 13, 2026 and 15.12M shares.
What is USPH's P/E?
USPH's P/E is 50.0, on earnings per share of -$1.34 over the last 12 months. The median over the last 5 fiscal years was 48.2.
How much revenue does USPH have?
U.S. Physical Therapy had revenue of $838M over the last 12 months. Over the last 5 years it changed by +13.1% a year on average.
Does USPH pay a dividend?
Yes. U.S. Physical Therapy paid $1.83 per share over the last 12 months, a yield of 1.84% at today's price. All the figures are in the Dividend section.
Where do the figures come from?
From U.S. Physical Therapy, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.